v3.25.2
Accrued Expenses and Other Current Liabilities
12 Months Ended
Jul. 02, 2025
Sep. 30, 2024
Sonnet BioTherapeutics Holdings, Inc. [Member]    
Accrued Expenses and Other Current Liabilities

3. Accrued Expenses and Other Current Liabilities

 

Accrued expenses and other current liabilities consisted of the following:

 

   June 30, 2025   September 30, 2024 
Compensation and benefits  $168,281   $149,802 
Research and development   777,846    617,545 
Professional fees   334,821    173,319 
Other   1,958    1,823 
 Accrued expenses and other current liabilities  $1,282,906   $942,489 

 

3. Accrued Expenses and Other Current Liabilities

 

Accrued expenses and other current liabilities consisted of the following:

 

   2024   2023 
   September 30, 
   2024   2023 
Compensation and benefits  $149,802   $2,091,196 
Research and development   617,545    913,145 
Professional fees   173,319    224,031 
Other   1,823    2,550 
Accrued expenses and other current liabilities  $942,489   $3,230,922 

 

During the first quarter of 2024, the Company cancelled accrued but unpaid bonuses that had been awarded for fiscal years 2022 and 2023, which has been accounted for as a change in estimate. The cancellation of bonuses reduced research and development expenses by $1.0 million and general and administrative expenses by $0.9 million for the year ended September 30, 2024.